Figure 4.

The strategy for gene delivery for CMs therapy. Gene therapy is a promising way to transduce exogenous gene expression. The two most common delivery methods are viral and non-viral vehicles. AAV is the most promising vector to delivery oligonucleotides. However, risk of high dosage of AAV administration limits its clinical practice. Thus, the mosaic genetic editing has been brought to reduce the requirement for AAV to avoid adverse effects. Besides, the non-viral delivery strategy is able to do transit gene expression, which works as an alternation to viral approach. Intramyocardial in situ and systematic injections are both able to achieve therapeutic goal.